After treatment with engineered exosomes, the CM from gastric cancer cells had a remarkably decreased ability to promote HUVEC cell proliferation, migration, and tube formation, indicating that this strategy may represent a new regimen for cancer therapy by suppressing SALL4/VEGF pathway via exosome-mediated drug delivery. This evidence concerns the gene SALL4 and cancer.